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ssociation of Atrial Natriuretic
eptide and Type A Natriuretic Peptide
eceptor Gene Polymorphisms With Left
entricular Mass in Human Essential Hypertension
peranza Rubattu, MD,*† Giada Bigatti, MD,‡ Anna Evangelista, PHD,* Chiara Lanzani, MD,‡
osita Stanzione, PHD,* Laura Zagato, BBSC,‡ Paolo Manunta, MD,‡ Simona Marchitti, BS,*
anessa Venturelli, MD,† Giuseppe Bianchi, MD,‡ Massimo Volpe, MD,*† Paola Stella, MD‡
ozzilli, Rome, and Milan, Italy
OBJECTIVES The goal of our study was to investigate the relationships between atrial natriuretic peptide
(ANP), brain natriuretic peptide (BNP), and type A natriuretic peptide receptor (NPRA)
gene polymorphisms and left ventricular structure in human essential hypertension.
BACKGROUND Experimental evidence supports a key role for natriuretic peptides in the modulation of
cardiac mass. This relationship has not yet been described in human disease.
METHODS A total of 203 hypertensive patients were studied by mono-bidimensional echocardiography.
Three markers of the ANP gene (C664G, G1837A, and T2238C polymorphisms) and a
microsatellite marker of both NPRA and BNP genes were characterized.
RESULTS Patients carrying the ANP gene promoter allelic variant had increased left ventricular mass
index (117.4  1.7 g vs. 95.7  1.7 g, p  0.005), left ventricular posterior wall thickness
(1.14  0.07 cm vs. 0.96  0.01 cm, p  0.0001), left ventricular septal thickness (1.12 
0.10 cm vs. 1.04  0.01 cm, p  0.01), and relative wall thickening (47.5  4.1% vs. 39.4 
5.3%, p  0.001) as compared with the wild-type genotype. These associations were
independent from anthropometric factors and major clinical features and were confirmed in
a large subgroup of never-treated hypertensive patients (n  148). Carrier status of the ANP
gene promoter allelic variant was associated with significantly lower plasma proANP levels:
1,395  104 fmol/ml versus 3,110  141 fmol/ml in hypertensive patients carrying the
wild-type genotype (p  0.05). A significant association for NPRA gene variants with left
ventricular mass index and left ventricular septal thickness was found. The analysis of BNP
did not reveal any effect on cardiac phenotypes.
CONCLUSIONS Our findings show that the ANP/NPRA system significantly contributes to ventricular
remodeling in human essential hypertension. (J Am Coll Cardiol 2006;48:499–505)
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.12.081© 2006 by the American College of Cardiology Foundation
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veft ventricular hypertrophy (LVH) is a common clinical
eature in hypertension and represents a powerful indepen-
ent risk factor for cardiovascular morbidity and mortality in
his condition (1). It is influenced by a number of factors,
ncluding blood pressure (BP) levels, age, gender, obesity,
See page 506
ietary habits, and pharmacological treatments (2,3). Hyper-
ension contributes only partially to the determination of
ardiac mass, whereas the role of genetic factors responsible for
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f Health (ICS 110.4/RF02353) to Dr. Bigatti.a
Manuscript received July 23, 2005; revised manuscript received December 7, 2005,
ccepted December 13, 2005.ardiac mass variance has been estimated up to 60% both in
umans (4,5) and in animal models (6). Identification of genes
nvolved in the development of LVH, considered as an
ntermediate disease phenotype, can provide useful clues to the
nderstanding of the complex etiopathogenesis of
ypertension-induced end-organ damage. The approach to the
nderstanding of the molecular genetic basis of LVH has been
ore successful, for obvious reasons, in animal models than in
umans (7).
Atrial natriuretic peptide (ANP) is a potent natriuretic
nd vasorelaxant hormone that is mainly secreted by cardi-
myocytes and plays a significant contributory role in
ardiovascular homeostasis (8). It has been shown recently
hat inactivation of the ANP gene (9) or of its receptor type
natriuretic peptide receptor (NPRA) (10) leads to a
ignificant increase of left ventricular mass (LVM), inde-
endently of BP levels. In contrast, elevation of ANP levels
n the heart seems to protect from hypertrophic stimuli,
hus supporting a protective role of ANP toward left
entricular enlargement (11). In vitro data confirm the
ntihypertrophic effect of ANP on cardiomyocytes in
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ANP/NPRA Polymorphisms and LVM August 1, 2006:499–505ulture (12). Experimental evidence also supports an
nvolvement of brain natriuretic peptide (BNP) in the
rocess of cardiac remodeling (13,14).
A functional deletion mutation of the 5=-flanking region
f the human type A natriuretic peptide receptor gene,
esponsible of reduced gene transcriptional activity, was
ound to confer increased susceptibility to essential hyper-
ension or LVH in a study performed in a Japanese
opulation (15). However, the question of whether ANP
nd BNP can directly modulate LVM, independently of
ypertension, remains unanswered for the human disease.
The present study was designed to investigate the rela-
ionships between natriuretic peptide gene molecular vari-
nts and left ventricular structure in a highly homogenous
opulation of middle-age Caucasian patients with mild to
oderate essential hypertension. To strengthen our findings
nd to rule out any long-term effects of antihypertensive
herapy (16), the analysis was repeated in a subgroup of
ever-treated hypertensive patients.
A positive association between ANP gene molecular
ariants and left ventricular mass index in essential hyper-
ension was found. This finding, although confirming the
xperimental evidence, represents the first demonstration of
he antihypertrophic role played by ANP in the process of
ardiac remodeling in human essential hypertension.
ETHODS
election of patients. Consecutive patients were recruited
t the outpatient clinic of the Division of Nephrology,
ialysis and Hypertension of the San Raffaele Hospital,
ilan. To minimize the environmental variability, the
nclusion criteria were very restrictive. Patients were re-
uired: 1) to be of the same race; 2) to have only essential
ypertension without collateral diseases with cardiovascular
mplications (i.e., diabetes); 3) to have not undergone
harmacological treatment for hypertension for at least 3
onths before the study and during the study; 4) to be not
bese (body mass index 30 kg/m2); and 5) to have normal
odium intake (24-h sodium excretion 300 mEq). This
election originated a population of 203 Caucasian patients
168 male, 35 female). All patients were Italians: 148
atients were never treated, and 55 patients had interrupted
Abbreviations and Acronyms
ANOVA  analysis of variance
ANP  atrial natriuretic peptide
BNP  brain natriuretic peptide
BP  blood pressure
LVH  left ventricular hypertrophy
LVM  left ventricular mass
NPRA  type A natriuretic peptide receptor
RFLP  restriction fragment length polymorphism
ST  septal thicknesshe pharmacological treatment 3 months before the study. wll patients provided an informed written consent. The
tudy protocol was approved by the local ethics committee.
P measurement. Hypertension was diagnosed, as previ-
usly reported (17), on the basis of the presence of systolic
P135 mm Hg and diastolic BP85 mm Hg by daytime
mbulatory BP monitoring (Spacelabs 90207, Redmond,
ashington) and of an office systolic BP140 mm Hg and
iastolic BP 90 mm Hg (average of 3 repeated measure-
ents made by the same doctor with a mercury
phygmomanometer).
iochemistry. Serum and urine electrolytes and creatinine
ere measured by standard methods (ion-selective electrode
nd autoanalyzer), and plasma renin activity and plasma
ldosterone with a radioimmunoassay (DiaSorin, Vercelli,
taly; and Medical System SpA, Genova, Italy). The aldo-
terone/plasma renin activity ratio was computed for each
atient.
easurement of LVH. Patients underwent mono-
imensional and bi-dimensional echocardiography using a
ewlett-Packard imaging system (Sonos 2500 model, Palo
lto, California). All measurements were performed by the
ame investigator, who was blinded to the patient’s
enotypes.
As previously reported (17), left ventricular internal
iameters, septal thickness (ST), and posterior wall thick-
ess were measured according to the guidelines of the
merican Society of Echocardiography (18). The LVM was
alculated at end diastole by applying the Devereux correc-
ion to the American Society of Echocardiography cube
VM formula (19). The relative wall thickening was calcu-
ated as previously reported (20).
Only patients with normal left ventricular function were
ncluded. Patients with either wall motion or cardiac valve
bnormalities were excluded.
enetic analysis of ANP, NPRA, and BNP. Extraction
f DNA from peripheral whole blood was done using a
ommercially available kit (Qiagen Italia SPA, Milan, Italy).
haracterization of ANP polymorphisms was performed by
reviously reported procedures (21). Briefly, we analyzed a
C664G promoter polymorphism by an RsaI restriction
ragment length polymorphism (RFLP) assay; an intronic
1837A polymorphism by an HpaII RFLP assay; and a
oding T2238C polymorphism by a ScaI RFLP assay. These
olymorphisms were previously shown to be in linkage
isequilibrium (21,22). For NPRA, we used a microsat-
llite marker localized within the promoter region (23).
or BNP, we used a microsatellite marker localized
ithin the 3= end of the gene (24).
All polymerase chain reactions were performed with a
TC-100 thermal cycler. Digestion with the corresponding
nzyme was carried out for the ANP markers as recom-
ended by the manufacturer (NEB, Boston, Massachu-
etts). The digested polymerase chain reaction products
ere resolved on agarose gels and visualized by ethidium
romide staining. Both NPRA and BNP microsatellites
ere amplified with 32P-labeled forward primer and unla-
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August 1, 2006:499–505 ANP/NPRA Polymorphisms and LVMeled reverse primer and visualized by autoradiography. The
enotypes were read by 2 blinded independent investigators.
easurement of plasma proANP levels. Fifteen hyper-
ensive patients carrying the wild-type genotype for the
NP promoter polymorphism and 5 heterozygous hyper-
ensive patients were randomly selected among the whole
ample.
To obtain more definite information on the functional
elevance of the ANP gene promoter variant, 12 normoten-
ive patients carrying the wild-type allele and 10 heterozy-
ous normotensive patients (from the same ethnic group as
he hypertensive population) were also included in the
nalysis. Plasma proANP levels were measured by the use of
sensitive enzyme-linked immunosorbent assay kit (Bio-
edica Gruppe, Wien, Austria).
tatistical analysis. All data are given as the mean value 
EM. Deviation from Hardy-Weinberg equilibrium was
nalyzed with the chi-square test. Differences between
roups were analyzed either by t test or 1-way analysis of
ariance (ANOVA) if groups were more than 2. The
ost-hoc least significant difference test was performed to
omplete the analysis for multiple comparisons. A covaried
-way ANOVA was performed considering each cardiac
arameter as a dependent variable; considering age, gender,
ody mass index, BP, duration of hypertension, 24-h
rinary Na output, and aldosterone/plasma renin activity
atio as covariates; and considering the polymorphism
howing significant differences in the analyses among
roups as an independent value. Analysis was performed
ith SPSS version 10 (SPSS Inc., Chicago, Illinois) for the
ac OS statistical software on an e-mac personal computer.
ESULTS
haracteristics of the study sample. Main anthropomet-
ic, clinical, and biochemical variables are reported in Table 1.
Here we report allele frequencies and chi-square test
esults for Hardy-Weinberg equilibrium for each genotype:
) ANP polymorphic markers:
a) C664G promoter polymorphism: 97.4% for the
644C allele and 2.6% for the 664G allele; chi-
square test: p  0.65
b) G1837A intronic polymorphism: 97.5% for the
1837G allele and 2.5% for the 1837A allele; chi-
square test: p  0.11
c) T2238C stop codon polymorphism: 2238T 83% for
the 2238T allele and 17% for the 2238C allele;
chi-square test: p  0.45
) NPRA polymorphism: Three allelic variants were iden-
tified for this microsatellite. Their frequency was 46.7%
for allele 10, 44.6% for allele 11, and 4.4% for allele 12;
chi-square test: p  0.38.
) BNP polymorphism: Five allelic variants were identified
for this microsatellite. Their frequency was 96.3% for the
wild-type allele and 3.7% for the combined mutant
alleles; chi-square test: p  0.83. eThe frequency of the observed genotypes was not differ-
nt from those expected from the allelic frequencies. The
ardy-Weinberg equilibrium was respected for all markers
s shown by chi-square significances.
NP gene polymorphisms and cardiovascular phenotypes.
C664G POLYMORPHISM. Among the whole sample, 192
atients were homozygous for the664C allele, 11 patients
ere heterozygous, and none homozygous for the 664G
llele was found. Among the subgroup of never-treated
atients, 142 patients were homozygous for the 664C
llele, 6 patients were heterozygous, and none homozygous
or the 664G allele were found.
No significant differences between the 2 genotypes
ere found by t test with regard to gender distribution,
ody mass index, BP levels, age, duration of hyperten-
ion, and 24-h urinary sodium excretion (Table 2). In
ontrast, the analysis of possible associations with echo-
ardiographic parameters showed that hypertensive pa-
ients who were carriers of the 664G allele had a
ignificantly increased posterior wall thickness and ST
nd an increased LVMI, whereas no significant differ-
nces were observed with regard to end-systolic and
able 1. Descriptive Anthropometric and Cardiac Variables of
he Whole Sample
Variables Mean  SEM
ge (yrs) 43.5  0.6
ody mass index (kg/m2) 26.0  0.2
stimated duration of hypertension (mo) 38.9  3.7
BP (mm Hg) 144.9  1.0
BP (mm Hg) 96.4  0.6
R (beats/min) 72.9  0.6
aytime SBP (mm Hg) 145.8  0.9
aytime DBP (mm Hg) 96.6  0.7
aytime HR (beats/min) 78.7  0.6
Na (mmol/l) 141.2  0.1
K (mmol/l) 4.1  0.02
FR (ml/min/BSA) 114.7  2.8
Na (mmol/day) 136.8  4.5
K (mmol/day) 54.0  1.4
RA (mg/ml · h) 1.664  0.10
ldosterone (pg/ml) 206.4  7.5
LDO/PRA ratio 180.8  9.6
A diameter (cm) 3.75  0.6
V septum (cm) 1.06  0.01
V PW (cm) 0.98  0.01
VIDD (cm) 4.96  0.03
VISD (cm) 2.94  0.03
WT (%) 39.9  5.1
VMI (g/m2) 97.4  1.5
F (%) 65.6  0.6
ldosterone  plasma aldosterone; ALDO/PRA  aldosterone/plasma renin activ-
ty; ANP  atrial natriuretic peptide; DBP  diastolic blood pressure; EF  ejection
raction; GFR  glomerular filtration rate; HR  heart rate; LA  left atrium
iameter; LV left ventricular; LVIDD left ventricular internal diastolic diameter;
VISD  left ventricular internal systolic diameter; LVMI  left ventricular mass
ndex; RWT  relative wall thickness; SBP  systolic blood pressure; sNa  serum
odium; sK  serum potassium; uK  24-h urinary potassium output; uNa 
4-h urinary sodium output.nd-diastolic diameters, left atrial diameter, or left ven-
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ANP/NPRA Polymorphisms and LVM August 1, 2006:499–505ricular function. These significant associations were
resent both in the overall population and in the sub-
roup of never-treated hypertensive patients (Table 3).
To better separate out the genetic effect, a covariate
NOVA was performed for each cardiac variable as de-
cribed in Methods section. The analysis results were
ignificant both in the whole sample and in the never-
reated subgroup, as shown in Table 4 (column titled “Total
odel”). In the same table, the R2 value enclosed within
rackets in the column titled “ANP” indicates the amount
f total variability explained by the effect of ANP polymor-
hism for each cardiac variable, independently of all
ovariates.
Measurement of circulating proANP levels in a subgroup
f both wild-type and heterozygous hypertensive patients
howed that the 664G allelic variant was associated with
significant decrease of proANP: 1,395 104 fmol/l versus
,110  141 fmol/ml in wild-type genotype individuals
p 0.05). In normotensive patients, plasma proANP levels
ere 1,165  47 fmol/ml versus 2,319  64 fmol/ml in
utant versus wild-type allele individuals (p  0.001).
1837A INTRONIC POLYMORPHISM. Among the whole sam-
le, 192 patients were homozygous for the 1837G allele and
0 patients were heterozygous; 1 patient homozygous for
he 1837A allele was joined to the heterozygous patients for
he analysis. Among the subgroup of never-treated patients,
43 individuals were homozygous for the 1837G allele, 5
atients were heterozygous, and none homozygous for the
Table 2. Clinical Variables According to the 
Variables
6
(n
Gender (M/F) 1
Age (yrs) 43
Body mass index (kg/m2) 25
Duration of hypertension (months) 38
SBP (mm Hg) 144
DBP (mm Hg) 96
HR (beats/min) 73
uNa (mmol/day) 130
*Analysis performed by t test for independent samples.
NS  not significant; other abbreviations as in Table 1.
able 3. Echocardiographic Variables According to the C664G
Variables
All Patients
664CC
(No. 192)
664CG
(No. 11)
A (cm) 3.66  0.07 4.05  0.40
V septum (cm) 1.04  0.01 1.12  0.10
V PW (cm) 0.96  0.01 1.14  0.07
VIDD (cm) 4.92  0.04 4.95  0.23
VISD (cm) 2.91  0.04 3.02  0.22
WT (%) 39.4  5.3 47.5  4.1
VMI (g/m2) 95.7  1.7 117.4  1.7
F (%) 65.8  0.6 63.8  3.1Analysis performed by t test for independent samples.
PW  posterior wall; other abbreviations as in Table 1.837A allele were found. No differences between the 2
enotypes were found with regard to either clinical or
ardiac variables by t test.
2238C POLYMORPHISM. Among the whole sample, 141
atients were homozygous for the 2238T allele, 53 patients
ere heterozygous, and 8 patients were homozygous for the
238C allele. Among the subgroup of never-treated pa-
ients, 101 patients were homozygous for the 2238T allele,
8 patients were heterozygous, and 7 patients were homozy-
ous for the 2238C allele.
No differences between genotypes with regard to clinical
ariables were seen by 1-way ANOVA.
To perform the analysis of this polymorphism with regard
o cardiac variables, patients carrying the variant allele were
oined because of the low number of double mutant allele
ndividuals. Interestingly, within the subgroup of never-
reated hypertensive patients an increase of LVMI was
etected in patients carrying the variant allele, although the
ignificance was reached only for ST (1.02  0.02 cm vs.
.09 0.03 cm in wild-type homozygotes vs. carriers of the
utant allele, respectively; p  0.03).
PRA receptor polymorphism. To perform the analysis,
ndividuals were grouped, based on the most common
enotypes, as follows: 10/10 (n  49), 10/11 (n  91),
1/11 (n  45), 11/12 (n  18) [whole sample] and 10/10
n  33), 10/11 (n  67), 11/11 (n  35), 11/12 (n  13)
never-treated subgroup]. No differences between genotypes
4G ANP Polymorphism Genotypes
2)
664CG
(n  11) p Value*
8/3 NS
.7 38.9  2.8 NS
.2 26.0  0.6 NS
.4 38.3  11.9 NS
.1 150.7  6.4 NS
.7 101.5  3.9 0.09
.7 70.5  2.5 NS
.1 117.3  17.7 NS
P Polymorphism Genotypes
Never-Treated Patients
alue*
664CC
(No. 142)
664CG
(No. 6) p Value*
S 3.73  0.08 3.97  0.55 NS
01 1.04  0.02 1.21  1.00 0.03
000 0.95  0.01 1.15  0.09 0.002
S 4.92  0.04 5.21  0.38 NS
S 2.91  0.04 3.01  0.34 NS
001 39.0  5.9 46.3  6.7 0.02
005 94.4  1.9 126.3  15.6 0.001
S 65.7  0.7 66.5  3.4 NSC66
64CC
 19
60/32
.5  0
.4  0
.8  4
.6  1
.2  0
.1  0
.1  4AN
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August 1, 2006:499–505 ANP/NPRA Polymorphisms and LVMith regard to clinical variables were seen by 1-way
NOVA (Table 5).
Carriers of the 11/12 genotype had significantly higher
alues of ST and LVMI versus all other genotypes in the
hole sample, whereas the significance was not reached in
he never-treated subgroup of patients despite the presence
f a similar trend (Table 6). Moreover, the significant
ssociation between the NPRA 11/12 genotype and
VMI was confirmed by the covariate ANOVA, after the
xclusion of the same confounding factors considered for
he ANP promoter polymorphism analysis (whole model:
 0.000, R2  28.6%; individual genotype effect: p 
.05; R2  5.3%).
Finally, because of the limited number of hypertensive
atients carrying both ANP and NPRA promoter gene
ariants, the analysis of possible epistatic interactions be-
ween the 2 genes on determination of LVMI was not
erformed.
NP polymorphism. The frequency of all allelic variants
n  5) for the BNP gene microsatellite marker was low. In
act, carriers of all allelic variants (13 patients) were grouped
or the analysis. No effect of the BNP gene variants on the
ardiovascular phenotypes considered in this study was
etected.
ISCUSSION
ur study shows that an ANP gene promoter variant,
esponsible for a significant downregulation of ANP gene
Table 4. One-Way ANOVA Adjusted for the
Index, BP, Duration of Hypertension, 24-h Ur
ANP C664G Polymorphism as Independent
Variables
All Patients
Total Model
p Value; (R2) p V
LV septum (cm) 0.000 (31.7%) 0.0
LV PW (cm) 0.000 (32.6%) 0.0
RWT (%) 0.000 (19.2%) 0.0
LVMI (g/m2) 0.000 (29.7%) 0.0
Each row represents a covaried 1-way analysis of variance of 1
both in the whole sample and in the subgroup of never-treate
(p value) and amount of variability (R2) explained by the com
value) and amount of variability (R2) explained by the effec
covariates.
ANOVA  analysis of variance; other abbreviation as in
able 5. Clinical Variables According to the NPRA Genotypes
Variables
1 (n  49)
(10/10)
2 (n
(10
ge (yrs) 43.4  1.6 42.2
ody mass index (kg/m2) 25.2  0.4 25.5
uration of hypertension (mo) 42.5  8.7 37.8
BP (mm Hg) 139.7  2.1 146.1
BP (mm Hg) 94.0  1.4 97.1
R (beats/min) 74.1  1.6 72.2
Na (mmol/day) 127.1  7.8 124.1Analysis performed by 1-way ANOVA with least-squares difference post-hoc test for mu
Abbreviations as in Table 1.ranscription, is associated with increased cardiac wall thick-
esses and LVMI in essential hypertension independently
rom BP levels as well as from anthropometric and clinical
actors. A role of NPRA gene molecular variants on the
etermination of LVMI was also found.
To identify the “true” genotype/phenotype relationships,
he study was performed in a hypertensive population
elected on the basis of very restrictive inclusion criteria. In
act, we enrolled patients with similar race, age, body
imensions, duration and stage of hypertension, and dietary
abits, and with no current pharmacological treatment.
emarkably, these findings were confirmed in a consider-
ble subgroup of never-treated hypertensive patients, allow-
ng us to completely rule out any pharmacological effect on
ardiac phenotypes (16).
Although the clinical relevance of our results is limited by
he low frequency of the ANP gene promoter variant, these
ndings, although confirming previous experimental evi-
ence, represent the first demonstration in humans of the
ntihypertrophic role played by ANP in the process of
ardiac remodeling in essential hypertension. Moreover,
reliminary echocardiographic examinations performed in
ormotensive patients carrying the promoter polymorphism
llelic variant have shown a trend for increased LVMI as
ompared with wild-type normotensive patients, thus sug-
esting an autocrine/paracrine role for ANP in the regula-
ion of ventricular mass that seems to be further enhanced in
he presence of hypertension.
owing Covariates: Age, Gender, Body Mass
Na Output, ALDO/PRA Ratio, With the
able
Never-Treated Patients
(R2)
Total Model
p Value; (R2)
ANP
p Value; (R2)
8%) 0.000 (29.8%) 0.007 (6.9%)
.1%) 0.000 (27.0%) 0.003 (8.4%)
.1%) 0.03 (14.8%) 0.02 (5.2%)
4%) 0.000 (28.2%) 0.004 (8.1%)
dual cardiac parameter, considered as the dependent variable,
nts. The columns titled Total Model report the significance
analysis. The columns titled ANP report the significance (p
e ANP gene promoter polymorphism independently of all
1.
) 3 (n  45)
(11/11)
4 (n  18)
(11/12) p Value*
0 43.8  1.4 45.9  1.7 NS
2 24.9  0.3 26.0  0.5 NS
9 31.9  8.6 54.4  19.8 NS
8 146.3  2.4 147.0  3.8 NS
1 96.3  1.4 99.5  2.6 NS
9 73.5  1.2 73.3  2.7 NS
9 141.5  9.1 131.2  14.3 NSFoll
inary
Vari
ANP
alue;
00 (8.
00 (13
00 (10
01 (7.
indivi
d patie
plete
t of th 91
/11)
 1.
 0.
 5.
 1.
 1.
 0.
 5.ltiple comparisons.
Lh
v
v
u
p
d
N
b
i
(
s
a
h
n
r
m
a
b
t
d
a
f
a
p
t
a
p
o
t
i
h
m
r
p
a
d
e
q
a
o
d
l
t
s
c
r
r
ple
6.
E
ch
oc
ar
di
og
ra
ph
ic
V
ar
ia
bl
es
A
cc
or
di
ng
to
th
e
N
P
R
A
G
en
ot
yp
es
V
ar
ia
bl
es
A
ll
P
at
ie
nt
s
N
ev
er
-T
re
at
ed
P
at
ie
nt
s
1
(n

49
)
(1
0/
10
)
2
(n

91
)
(1
0/
11
)
3
(n

45
)
(1
1/
11
)
4
(n

18
)
(1
1/
12
)
p
V
al
ue
*
1
(n

33
)
(1
0/
10
)
2
(n

67
)
(1
0/
11
)
3
(n

35
)
(1
1/
11
)
4
(n

13
)
(1
1/
12
)
p
V
al
ue
*
se
pt
um
(c
m
)
1.
05

0.
03
1.
03

0.
02
1.
02

0.
03
1.
19

0.
08
†
0.
01
1.
04

0.
04
1.
02

0.
02
1.
04

0.
04
1.
13

0.
07
N
S
P
W
(c
m
)
0.
95

0.
03
0.
98

0.
01
0.
99

0.
02
1.
05

0.
05
N
S
0.
93

0.
03
0.
94

0.
02
0.
99

0.
03
1.
02

0.
06
N
S
ID
D
(c
m
)
4.
88

0.
07
4.
93

0.
06
4.
92

0.
08
5.
09

0.
12
N
S
4.
85

0.
09
5.
00

0.
07
4.
89

0.
10
5.
07

0.
14
N
S
IS
D
(c
m
)
2.
87

0.
06
2.
93

0.
06
2.
90

0.
09
3.
02

0.
12
N
S
2.
88

0.
08
2.
93

0.
06
2.
90

0.
09
2.
94

0.
13
N
S
T
(%
)
38
.9

1.
2
39
.7

0.
7
41
.0

1.
3
41
.7

2.
5
N
S
38
.4

1.
3
38
.7

0.
8
41
.0

1.
6
40
.7

2.
5
N
S
M
I
(g
/m
2 )
95
.4

4.
1
94
.7

2.
3
97
.0

3.
4
11
5.
0

8.
4†
0.
02
92
.3

4.
9
93
.8

2.
6
97
.6

3.
7
10
9.
3

9.
5
N
S
(c
m
)
3.
53

0.
01
3.
64

0.
01
3.
99

0.
02
3.
80

0.
02
N
S
3.
60

0.
01
3.
65

0.
01
4.
11

0.
02
3.
75

0.
01
N
S
(%
)
66
.0

0.
9
65
.3

1.
0
66
.1

1.
2
65
.6

1.
8
N
S
65
.8

1.
2
65
.5

1.
1
65
.9

1.
4
67
.3

1.
9
N
S
al
ys
is
pe
rf
or
m
ed
by
1-
w
ay
A
N
O
V
A
w
ith
le
as
t-
sq
ua
re
s
di
ffe
re
nc
e
po
st
-h
oc
te
st
fo
r
m
ul
tip
le
co
m
pa
ri
so
ns
.†
V
er
su
s
al
lo
th
er
ge
no
ty
pe
s.
bb
re
vi
at
io
ns
as
in
T
ab
le
1.
504 Rubattu et al. JACC Vol. 48, No. 3, 2006
ANP/NPRA Polymorphisms and LVM August 1, 2006:499–505Our data support previous evidence of a role of NPRA on
VM in human hypertension (15).
The natriuretic peptides are mainly produced within the
eart and are involved in the regulation of BP and blood
olume through their direct effects on kidney and systemic
asculature (24). An important contributory role of natri-
retic peptides in the regulation of cellular growth, cellular
roliferation, and cardiac hypertrophy has been recently
ocumented. All effects are primarily mediated through the
PRA receptor (25). In particular, a strong relationship
etween ANP/NPRA and LVM has been so far convinc-
ngly shown only in genetically manipulated animal models
9,10,11,26,27). Based on these findings, the ANP-NPRA
ystem seems to behave as a relevant regulatory mechanism
ntagonizing hypertrophic growth responses within the
eart. Thus, the increase of ANP that generally accompa-
ies cardiac hypertrophy should be interpreted as the
esponse of an intrinsic “friendly” mechanism that protects
yocardiocytes against hypertrophic stimuli (28,29).
To further strengthen the interpretation of the results from
ssociation studies, it is important to establish a plausible
iological explanation for observed statistical relationships be-
ween gene polymorphisms and pathological phenotypes. Our
ata provided good evidence for a biological link for the
ssociation between ANP and cardiac variables. In fact, we
ound that carrier status of the promoter allelic variant was
ssociated with significantly lower levels of circulating
roANP. The latter represents the most reliable marker of the
otal amount of secreted ANP because of its longer half-life
nd higher stability as compared with alpha-ANP, for which a
arallel trend for lower levels in mutant allele patients was also
bserved (data not shown). Our findings parallel those ob-
ained in ANP knockout mice. The C664G polymorphism
s located within a portion of the 5= flanking sequence of the
uman gene containing a series of cis-acting regulatory ele-
ents able to modulate ANP gene expression (30–32). Our
esults cannot exclude the possibility that another polymor-
hism in linkage disequilibrium with the C664G locus
ctually causes the phenotype.
A stop codon polymorphism was associated with a certain
egree of cardiac mass remodeling. The stop codon variant adds 2
xtra arginine residues to alpha-ANP, and its functional conse-
uences are still unknown. We previously reported its significant
ssociation with an increased risk of ischemic stroke (21), whereas
ther studies have shown its contributory role to hypertensive renal
amage (33) and to ischemic cardiac disease (34).
The NPRA gene molecular variant used in this study is
ocated within the 5= flanking region, and its effect on the
ranscriptional activity is unknown (23). The results of our
tudy, showing a significant effect on LVMI in patients
arrying the mutant alleles, suggest that the functional
elevance of the promoter gene variants may be related to a
educed NPRA activity.
Finally, the BNP gene was unrelated to all cardiovascular
henotypes considered in this study, and particularly toLVMI. This negative result, which does not support previ-Ta
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August 1, 2006:499–505 ANP/NPRA Polymorphisms and LVMus observations (13,14), may be partly explained by the low
requency of allelic variants detected in our population
although it was slightly higher than that observed for the
NP promoter and NPRA gene variants) and most prob-
bly by the location of this marker within the 3= end of the
ene. It is likely that the characterization of a more
unctionally significant gene marker may have led to differ-
nt results. Moreover, the lack of measurement of BNP
evels can be considered as a limitation of our study.
onclusions. The present study shows an association be-
ween ANP/NPRA gene polymorphisms and left ventricu-
ar structure in human essential hypertension. A reduced
roANP level mediates the observed increase in LVMI in
arriers of the ANP gene promoter variant, whereas a
educed NPRA activity is most likely responsible for the
ame phenotype. Our data, although confirming the anti-
ypertrophic role of ANP/NPRA toward the hypertrophic
rowth response previously obtained in experimental mod-
ls, provide the first evidence that the ANP/NPRA system
egulates LVM in human hypertension.
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